An J - Search Results

1

Tuning the Organ Tropism of Polymersome for Spleen-Selective Nanovaccine Delivery to Boost Cancer Immunotherapy.

Gu W, An J, Li Y, Yang Y, Wang S, Shan H, Li S, Li H, Liu G, Li K, Yin Y, Mu J, Chen X. Gu W, et al. Among authors: an j. Adv Mater. 2023 Oct;35(41):e2301686. doi: 10.1002/adma.202301686. Epub 2023 Jun 30. Adv Mater. 2023. PMID: 37165781

2

CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma.

Gu W, An J, Meng H, Yu N, Zhong Y, Meng F, Xu Y, Cornelissen JJLM, Zhong Z. Gu W, et al. Among authors: an j. Adv Mater. 2019 Nov;31(46):e1904742. doi: 10.1002/adma.201904742. Epub 2019 Sep 27. Adv Mater. 2019. PMID: 31560141

3

CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia.

Zhang Y, An J, Shao Y, Yu N, Yue S, Sun H, Zhang J, Gu W, Xia Y, Zhang J, Xu Y, Zhong Z. Zhang Y, et al. Among authors: an j. Biomacromolecules. 2022 Jan 10;23(1):377-387. doi: 10.1021/acs.biomac.1c01342. Epub 2021 Dec 16. Biomacromolecules. 2022. PMID: 34913676

4

Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia.

Xia Y, An J, Li J, Gu W, Zhang Y, Zhao S, Zhao C, Xu Y, Li B, Zhong Z, Meng F. Xia Y, et al. Among authors: an j. Bioact Mater. 2022 Sep 20;21:499-510. doi: 10.1016/j.bioactmat.2022.08.032. eCollection 2023 Mar. Bioact Mater. 2022. PMID: 36185744 Free PMC article.

5

Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukemia.

Yue S, An J, Zhang Y, Li J, Zhao C, Liu J, Liang L, Sun H, Xu Y, Zhong Z. Yue S, et al. Among authors: an j. Adv Mater. 2023 Aug;35(32):e2209984. doi: 10.1002/adma.202209984. Epub 2023 Jun 30. Adv Mater. 2023. PMID: 37321606

6

Corrigendum to "Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia" [Bioact. Mater. 21 (March 2023) 499-510].

Xia Y, An J, Li J, Gu W, Zhang Y, Zhao S, Zhao C, Xu Y, Li B, Zhong Z, Meng F. Xia Y, et al. Among authors: an j. Bioact Mater. 2023 Aug 21;31:312-314. doi: 10.1016/j.bioactmat.2023.08.011. eCollection 2024 Jan. Bioact Mater. 2023. PMID: 37637085 Free PMC article.

7

Correction to "CD38-Directed Vincristine Nanotherapy for Acute Lymphoblastic Leukemia".

Zhang Y, An J, Shao Y, Yu N, Yue S, Sun H, Zhang J, Gu W, Xia Y, Zhang J, Xu Y, Zhong Z. Zhang Y, et al. Among authors: an j. Biomacromolecules. 2022 Jul 11;23(7):3041. doi: 10.1021/acs.biomac.2c00732. Epub 2022 Jun 27. Biomacromolecules. 2022. PMID: 35759396 No abstract available.

8

A Novel IL3-ETV6 Fusion in Chronic Eosinophilic Leukemia Not Otherwise Specified With t(5; 12) (q31; p13): A Case Report and Literature Review.

Zhao C, Wang M, Zhan Y, Xu Y, Chen S, Wang Q, An J, Liu T. Zhao C, et al. Among authors: an j. Front Oncol. 2022 Jun 7;12:887945. doi: 10.3389/fonc.2022.887945. eCollection 2022. Front Oncol. 2022. PMID: 35747804 Free PMC article.

9

Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.

Zhou L, An J, Hou C, Ding Z, Qiu H, Tang X, Sun A, Chen S, Xu Y, Liu T, Wu D. Zhou L, et al. Among authors: an j. Hematology. 2021 Dec;26(1):340-347. doi: 10.1080/16078454.2021.1905356. Hematology. 2021. PMID: 33840380

10

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D).

An J, Ding S, Li S, Sun L, Chang X, Huang Z, Zhou B, Fang C, Liu C, Zhang X. An J, et al. J Immunol Res. 2019 Aug 1;2019:1780567. doi: 10.1155/2019/1780567. eCollection 2019. J Immunol Res. 2019. PMID: 31467932 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,675 results

Search Page